Search | IOVS | ARVO Journals

View

Showing 1 – 5 of 5

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

5-year outcome of initial treatment with ranibizumab monotherapy for polypoidal choroidal vasculopathy with good visual acuity

Takeya Kohno; Manabu Yamamoto; Tomoko Tamachi; Jyunji Asai; Natsuko Oishi; Shinsuke Ataka; Ayako Yasui; Akira Cho; Michiko Hirabayashi; Kunihiko Shiraki

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):880. doi:

ARVO Annual Meeting Abstract June 2017

One year outcome of treat and extend regimen of aflibercept for polypoidal choroidal vasculopathy

Tomoko Tamachi; Takeya Kohno; Akika Kyo; Manabu Yamamoto; Natsuko Oishi; Jyunji Asai; Shinsuke Ataka; Ayako Yasui; Akira Cho; Michiko Hirabayashi; Kunihiko Shiraki

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):885. doi:

ARVO Annual Meeting Abstract September 2016

2-year results of switching to aflibercept for polypoidal choroidal vasculopathy in patients refractory to ranibizumab

Takeya Kohno; Manabu Yamamoto; Akira Cho; Kumiko Hirayama; Ayako Yasui; Shinsuke Ataka; Michiko Hirabayashi; Kunihiko Shiraki

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):514. doi:

ARVO Annual Meeting Abstract June 2015

Changes of Fundus Autofluorescence after Reduced Fluence Photodaynamic Therapy with Verteporfin in Patients with Central Serous Choroiretinopahty

Takeya Kohno; Manabu Yamamoto; Kumiko Yoshimoto; Akira Cho; Shogo Ogawa; Michiko Hirabayashi; Tomohiro Ikeda; Kunihiko Shiraki

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3729. doi:

ARVO Annual Meeting Abstract April 2014

Six-month results of switching to aflibercept for polypoidal choroidal vasculopathy in patients refractory to ranibizumab

Takeya Kohno; Manabu Yamamoto; Akira Cho; Yusaku Yoshida; Hisashi Iwami; Yuta Sawa; Kumiko Yoshimoto; Michiko Hirabayashi; Kunihiko Shiraki

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3839. doi:

Advertisement